___

• 1. Al-Sweih NA, Al-Hubail MA, Rotimi VO. Emergence of tigecycline and colistin resistance in Acinetobacter species isolated from patients in Kuwait hospitals, J Chemother 2011;23(1):13-6. https://doi.org/10.1179/joc.2011.23.1.13
• 2. Arroyo LA, Mateos I, Gonzalez V et al. In vitro activities of tigecycline, minocycline, and colistin-tigecycline combination against multi- and pandrug-resistant clinical isolates of Acinetobacter baumannii group, Antimicrob Agents Chemother 2009;53(3):1295-6. https://doi.org/10.1128/AAC.01097-08
• 3. Boucher HW, Talbot GH, Bradley JS et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America, Clin Infect Dis 2009;48(1):1-12. https://doi.org/10.1086/595011
• 4. Bshabshe AA, Joseph MRP, Hussein AA, Haimour W, Hamid ME. Multidrug resistance Acinetobacter species at the intensive care unit, Aseer Central Hospital, Saudi Arabia: a one year analysis, Asian Pac J Trop Med 2016;9(9):903-8. https://doi.org/10.1016/j.apjtm.2016.07.016
• 5. Clinical breakpoints (Bacterial v6.0 and Fungal v8.0). The European Committee on Antimicrobial Susceptibility Testing: http:// www.eucast.org/clinical_breakpoints.
• 6. Dizbay M, Altuncekic A, Sezer BE et al. Colistin and tigecycline susceptibility among multidrug-resistant Acinetobacter baumannii isolated from ventilator-associated pneumonia, Int J Antimicrob Agents 2008;32(1):29- 32. https://doi.org/10.1016/j.ijantimicag.2008. 02.016
• 7. Dobrewski R, Savov E, Bernards AT et al. Genotypic diversity and antibiotic susceptibility of Acinetobacter baumannii isolates in a Bulgarian hospital, Clin Microbiol Infect 2006;12(11):1135-7. https://doi.org/10.1111/j.1469-0691.2006.01530.x
• 8. Doi Y, Husain S, Potoski BA, McCurry KR, Paterson DL. Extensively drug-resistant Acinetobacter baumannii, Emerg Infect Dis 2009;15(6):980-2. https://doi.org/10.3201/eid1506.081006
• 9. Eser OK, Ergin A, Hascelik G. Antimicrobial resistance and existence of metallo-blactamase in Acinetobacter species isolated from adult patients, Mikrobiyol Bul 2009;43(3): 383-90.
• 10. Falagas ME, Vardakas KZ, Roussos NS. Trimethoprim/sulfamethoxazole for Acinetobacter spp.: areview of current microbiological and clinical evidence, Int J Antimicrob Agents 2015;46(3):231-41. https://doi.org/10.1016/j.ijantimicag.2015.04.002
• 11. Garcia-Penuela E, Aznar E, Alarcon T, LópezBrea M. Susceptibility pattern of Acinetobacter baumannii clinical isolates in Madrid vs. Hong Kong, Rev Esp Quimioter 2006;19(1):45- 50.
• 12. Garonzik SM, Li J, Thamlikitkul V et al. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients, Antimicrob Agents Chemother 2011;55(7):3284-94. https://doi.org/10.1128/AAC.01733-10
• 13. Gündoğdu A, Ulu Kılıç A, Kılıç H, Alp Meşe E. Kolistin dirençli gram-olumsuz mikroorganizmaların klinik ve epidemiyolojisi: Hastanelerde yeni tehdit, 6. Türkiye EKMUD Kongresi Kitabı, s.37 Antalya (2016).
• 14. Hawley JS, Murray CK, Griffith ME et al. Susceptibility of Acinetobacter strains isolated from deployed U.S. military personel, Antimicrob Agents Chemother 2007;51(1): 376-8. https://doi.org/10.1128/AAC.00858-06
• 15. Hejnar P, Kol B. E. Sezer ve ark. 38 Acinetobacter strains (phenotype classification, antibiotic susceptibility and production of b-lactamases) isolated from haemocultures from patients at the Teaching Hospital in Olomouc, Acta Univ Palacki Olomuc Fac Med 1999;142:73-7.
• 16. Hornsey M, Wareham DW. In vivo efficacy of glycopeptide-colistin combination therapies in a Galleria mellonella model of Acinetobacter baumannii infection, Antimicrob Agents Chemother 2011;55(7):3534-7. https://doi.org/10.1128/AAC.00230-11
• 17. http://www.saglikaktuel.com/d/file/ulusal_ozet_raporu_22_07_2016.pdf
• 18. Ko KS, Suh JY, Kwon KT et al. High rates of resistance to colistin and polymyxin B in subgroups of Acinetobacter baumannii isolates from Korea, J Antimicrob Chemother 2007;60(5):1163-7. https://doi.org/10.1093/jac/dkm305
• 19. Maragakis LL, Perl TM. Acinetobacter baumannii: epidemiology, antimicrobial resistance, and treatment options, Clin Infect Dis 2008;46(8):1254-63. https://doi.org/10.1086/529198
• 20. Mezzatesta ML, Trovato G, Gona F et al. In vitro activity of tigecycline and comparators against carbapenem-susceptible and resistant Acinetobacter baumannii clinical isolates in Italy, Ann Clin Microbiol Antimicrob 2008;7:4. https://doi.org/10.1186/1476-0711-7-4
• 21. Nastro M, Rodriguez CH, Monge R et al. Activity of the colistin-rifampicin combination against colistin- resistant, carbapenemaseproducing Gram-negative bacteria, J Chemother 2014;26(4):211-6. https://doi.org/10.1179/1973947813Y.00000 00136
• 22. O’Hara JA, Ambe LA, Casella LG et al . Activities of vancomycin-containing regimens against colistin-resistant Acinetobacter baumannii clinical strains, Antimicrob Agents Chemother 2013;57(5): 2103-8. https://doi.org/10.1128/AAC.02501-12
• 23. Quinteira S, Grosso F, Ramos H et al. Molecular epidemiology of imipenemresistant Acinetobacter haemolyticus and Acinetobacter baumannii isolates carrying plasmid-mediated OXA-40 from a Portuguese hospital, Antimicrob Agents Chemother 2007;51(9):3465-6. https://doi.org/10.1128/AAC.00267-07
• 24. Rozenberg-Arska M, Dekker AW, Verhoef J. Colistin and trimethoprim-sulfamethoxazole for the prevention of infection in patients with acute non-lymphocytic leukaemia. Decrease in the emergence of resistant bacteria, Infection 1983;11(3):167-9. https://doi.org/10.1007/BF01641298
• 25. Santimaleeworagun W, Wongpoowarak P, Chayakul P, Pattharachayakul S, Tansakul P, Garey KW. In vitro activity of colistin or sulbactam in combination with fosfomycin or imipenem against clinical isolates of carbapenem-resistant Acinetobacter baumannii producing OXA-23 carbapenemases, Southeast Asian J Trop Med Public Health 2011;42(4):890-900.
• 26. Tasina E, Haidich AB, Kokkali S et al. Efficacy and safety of tigecycline for the treatment of infectious diseases: a meta-analysis, Lancet Infect Dis 2011;11(11):834-44. https://doi.org/10.1016/S1473-3099(11)70177-3
• 27. Timurkaynak F, Can F, Azap OK, Demirbilek M, Arslan H, Karaman SO. In vitro activities of non-traditional antimicrobials alone or in combination against multidrug-resistant strains of Pseudomonas aeruginosa and Acinetobacter baumannii isolated from intensive care units, Int J Antimicrob Agents 2006;27(3):224-8. https://doi.org/10.1016/j.ijantimicag.2005.10.012
• 28. Vidaillac C, Benichou L, Duval RE. In vitro synergy of colistin combinations against colistin-resistant Acinetobacter baumannii, Kolistin dirençli Acinetobacter baumanii tedavisinde sıra dışı bir antibiyotik kombinasyon tedavisi: Trimetoprim-Sülfametoksazol ve kolistin kombinasyonu 39 Pseudomonas aeruginosa, and Klebsiella pneumoniae isolates, Antimicrob Agent Chemother 2012;56(9):4856-61. https://doi.org/10.1128/AAC.05996-11
• 29. Yilmaz GR, Dizbay M, Guven T et al. Risk factors for infection with colistin-resistant gram-negative microorganisms: a multicenter study, Ann Saudi Med 2016;36(3):216-22. https://doi.org/10.5144/0256-4947.2016.216